Randomized controlled trial

In 1747, James Lind conducted the first reported clinical trial to identify a treatment for scurvy, marking a pivotal moment in medical history. Lind, a Scottish physician serving on the HMS Salisbury, divided twelve scurvy patients into six pairs and gave each pair a different treatment, including cider, vinegar, and citrus fruits. The results were striking: the pair receiving oranges and lemons showed rapid recovery, while the others showed little improvement. This experiment laid the groundwork for the concept of controlled trials, though it lacked the randomization that would later define the modern randomized controlled trial. Lind's work was a precursor to the rigorous methods that would emerge centuries later, yet it demonstrated the power of comparing treatments systematically. The trial's simplicity and clarity made it a landmark in medical science, proving that even without randomization, structured comparison could yield life-saving insights.

The Birth of Randomization

The concept of randomization in clinical trials emerged in the early 20th century, revolutionizing how researchers approached experimental design. In 1948, the Medical Research Council published a groundbreaking paper titled Streptomycin treatment of pulmonary tuberculosis, which is widely regarded as the first randomized controlled trial in medicine. Austin Bradford Hill, one of the study's authors, conceived the modern RCT by randomly assigning patients to receive either streptomycin or bed rest alone. The trial's success demonstrated that randomization could eliminate selection bias and confounding factors, ensuring that the results were not skewed by pre-existing differences between patient groups. This method became the gold standard for clinical research, enabling scientists to draw reliable conclusions about treatment efficacy. The trial's impact was immediate, as it provided the first robust evidence that streptomycin could effectively treat tuberculosis, saving countless lives and setting a precedent for future medical research.

The Ethics of Randomization

The ethical implications of randomized controlled trials have been a subject of intense debate since their inception. While participants in RCTs typically provide informed consent, studies since 1982 have shown that many subjects believe they are certain to receive the best treatment for their condition, a phenomenon known as therapeutic misconception. This misunderstanding complicates the process of obtaining informed consent, as patients may not fully grasp the difference between research and treatment. Placebo-controlled trials, in particular, have faced ethical scrutiny, especially when withholding treatment could lead to harm or death. The principle of clinical equipoise, which requires genuine uncertainty within the medical community about the preferred treatment, is often difficult to ascertain. Ethical dilemmas arise when equipoise conflicts with personal beliefs, such as a patient's conviction that an intervention is effective. These challenges have led to the development of alternative trial designs, such as crossover trials and active-controlled trials, though these options are not always suitable. The ethical landscape of RCTs continues to evolve, balancing the need for rigorous scientific evidence with the moral obligation to protect patient well-being.

Common questions

Who conducted the first reported clinical trial for scurvy in 1747?

James Lind conducted the first reported clinical trial for scurvy in 1747 while serving as a Scottish physician on the HMS Salisbury. He divided twelve scurvy patients into six pairs and tested different treatments including cider, vinegar, and citrus fruits. The pair receiving oranges and lemons showed rapid recovery while the others showed little improvement.

When was the first randomized controlled trial in medicine published?

The first randomized controlled trial in medicine was published in 1948 by the Medical Research Council. The paper titled Streptomycin treatment of pulmonary tuberculosis was authored by Austin Bradford Hill who conceived the modern RCT by randomly assigning patients to receive either streptomycin or bed rest alone. This trial demonstrated that randomization could eliminate selection bias and confounding factors.

What is the therapeutic misconception in randomized controlled trials since 1982?

Studies since 1982 have shown that many subjects believe they are certain to receive the best treatment for their condition which is known as the therapeutic misconception. This misunderstanding complicates the process of obtaining informed consent as patients may not fully grasp the difference between research and treatment. Placebo-controlled trials have faced ethical scrutiny especially when withholding treatment could lead to harm or death.

How much did 28 Phase III RCTs funded by the National Institute of Neurological Disorders and Stroke cost before 2000?

A study of 28 Phase III RCTs funded by the National Institute of Neurological Disorders and Stroke prior to 2000 revealed a total cost of US$335 million. The average cost per trial was US$12 million despite the high financial burden. The same study projected that these 28 RCTs produced a net benefit to society at 10 years of 46 times the cost of the trials program.

What percentage of 509 RCTs included in 29 meta-analyses were industry-funded in 2011?

A 2011 study reviewing 29 meta-analyses found that 219 out of 509 RCTs were industry-funded which represents 69% of the total. Of these 509 RCTs 91 studies disclosed industry financial ties with one or more authors. A systematic review published in 2003 found a correlation between industry sponsorship and positive study outcomes with industry-funded RCTs being more likely to report statistically significant pro-industry findings.